<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571921</url>
  </required_header>
  <id_info>
    <org_study_id>896.128</org_study_id>
    <nct_id>NCT01571921</nct_id>
  </id_info>
  <brief_title>Gamma-delta Tocotrienol as Potential Maintenance Treatment in Women With Metastatic Breast Cancer</brief_title>
  <acronym>GEMM1a</acronym>
  <official_title>Phase 1a: A Randomized, 2-period Cross-over Study to Compare the Bioavailability of Gamma-Delta Tocotrienol (GDT) With That of Tocotrienol Rich Fraction (TRF) in Twelve Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malaysia Palm Oil Board</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Malaysia Palm Oil Board</source>
  <brief_summary>
    <textblock>
      Twelve healthy volunteers who fit the inclusion and exclusion criteria and provide written
      informed consent to participate in the trial will be recruited to compare the rate and extent
      of absorption and pharmacokinetics of the newly formulated Gamma-Delta formulation with TRF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve healthy subjects will be admitted to a clinical study ward on the Day 0. Physical
      check up and the health status will be confirmed during check in. After fasting for a minimum
      of 10 hours overnight, each subject will be administered a single dose of TRF or Gamma-Delta
      after taking a standardized high-fat meal breakfast on Day 1. Thereafter, standard meals will
      be provided at 4 and 12 hours after dosing. Blood samples (5mL will be taken using an
      in-dwelling canula placed in the antecubital vein immediately before and at 0.5, 1, 2, 3, 4,
      5, 6, 7, 8, 10, 14, and 24 hours after dosing. Subjects will be admitted for 24 hours and
      discharged after the last blood sampling. During the study, blood pressure and the heart rate
      will be monitored regularly for safety profile.

      After a one week wash out period, subject will return to the ward and be given the other
      formulation (TRF or GDT) and the same procedures will be repeated. Any adverse events that
      arise during the treatment will be recorded and followed up till resolution.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)of drug</measure>
    <time_frame>0 to 24 hours after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Gamma-Delta Tocotrienol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction</intervention_name>
    <description>Single oral TRF or Gamma-Delta Tocotrienol dosage</description>
    <arm_group_label>Gamma-Delta Tocotrienol</arm_group_label>
    <arm_group_label>TRF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 21-55 years old

          -  Good health

          -  No allergy to vitamin E/ palm oil

          -  No past (within 3 months) / current use of dietary supplements containing vitamin E

        Exclusion Criteria:

          -  History of bleeding tendencies or any condition predisposing to bleeding e.g.
             thrombocytopenia, abnormal liver function, liver disease (e.g. chronic hepatitis),
             gastrointestinal ulcers

          -  Candidate for surgery or had undergone surgery in the past 6 months

          -  Current or past use (last 3 months) of antithrombotic drugs such as antiplatelets
             (aspirin, ticlopidine), anticoagulants (heparin, warfarin), thrombolytic agents
             (streptokinase), etc

          -  Current or past history of cancer

          -  Pregnant/ breastfeeding women

          -  Smokers

          -  Drug or alcohol abuse

          -  Hypercholesterolemia

          -  Chronic conditions such as uncontrolled hypertension, heart disease (ischemic heart
             disease, heart failure, cardiac arrhythmia), uncontrolled diabetes, HIV infection, or
             other psychiatric illness/ social situations that might limit adherence to study
             protocol.

          -  Unable or unwilling to stop taking vitamins, herbal preparations or nonprescription
             medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nur Aishah Mohd Taib</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Malaya Medical Centre(UMMC)</name>
      <address>
        <city>Lembah Pantai,</city>
        <state>Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, Shneker B, Ganesh K, Phillips G, More JL, Sarkar A, Kirkpatrick R, Elkhammas EA, Klatte E, Miller M, Firstenberg MS, Chiocca EA, Nesaretnam K, Sen CK. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012 Mar;142(3):513-9. doi: 10.3945/jn.111.151902. Epub 2012 Feb 1.</citation>
    <PMID>22298568</PMID>
  </reference>
  <reference>
    <citation>Mahalingam D, Radhakrishnan AK, Amom Z, Ibrahim N, Nesaretnam K. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. Eur J Clin Nutr. 2011 Jan;65(1):63-9. doi: 10.1038/ejcn.2010.184. Epub 2010 Sep 22.</citation>
    <PMID>20859299</PMID>
  </reference>
  <reference>
    <citation>Zaiden N, Yap WN, Ong S, Xu CH, Teo VH, Chang CP, Zhang XW, Nesaretnam K, Shiba S, Yap YL. Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion. J Atheroscler Thromb. 2010 Oct 27;17(10):1019-32. Epub 2010 Aug 10.</citation>
    <PMID>20702976</PMID>
  </reference>
  <reference>
    <citation>Comitato R, Nesaretnam K, Leoni G, Ambra R, Canali R, Bolli A, Marino M, Virgili F. A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERbeta signal transduction. Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E427-37. doi: 10.1152/ajpendo.00187.2009. Epub 2009 Jun 2.</citation>
    <PMID>19491296</PMID>
  </reference>
  <reference>
    <citation>Weng-Yew W, Selvaduray KR, Ming CH, Nesaretnam K. Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. Nutr Cancer. 2009;61(3):367-73. doi: 10.1080/01635580802582736.</citation>
    <PMID>19373610</PMID>
  </reference>
  <results_reference>
    <citation>Nesaretnam K, Selvaduray KR, Abdul Razak G, Veerasenan SD, Gomez PA. Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res. 2010;12(5):R81. doi: 10.1186/bcr2726. Epub 2010 Oct 8.</citation>
    <PMID>20929592</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Malaysia Palm Oil Board</investigator_affiliation>
    <investigator_full_name>Puvaneswari Meganathan</investigator_full_name>
    <investigator_title>Ms</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

